← Bio-Techne overview

Bio-Techne vs Illumina: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Bio-Techne Corp (TECH)

Q3 2026
▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

  • Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.

    This is the latest and most important step in the buyout that now defines TECH's price.

  • Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.

    It is a new, concrete regulatory clearance that directly supports deal completion.

  • Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.

    It shows the acquirer is financially strong and committed, which supports the deal price.

  • Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.

    It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

August 2026
▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

  • Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.

    This is the latest and most important step in the buyout that now defines TECH's price.

  • Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.

    It is a new, concrete regulatory clearance that directly supports deal completion.

  • Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.

    It shows the acquirer is financially strong and committed, which supports the deal price.

  • Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.

    It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Latest
▲3

Bio-Techne's $73-a-share Merck buyout clears shareholder vote and antitrust review

  • Shareholders approve Merck KGaA buyout On September 23, 2026, Bio-Techne shareholders voted to approve the $73-per-share cash buyout by Merck KGaA. This locks in the deal price and moves the company closer to closing, so the stock should trade near $73 rather than on its own business results.

    This is the latest and most important step in the buyout that now defines TECH's price.

  • Antitrust waiting period expires The U.S. antitrust waiting period under the Hart-Scott-Rodino Act expired on September 18, 2026. That removes a major regulatory hurdle, making it more likely the deal closes on schedule and reducing the risk that the $73 price falls through.

    It is a new, concrete regulatory clearance that directly supports deal completion.

  • Merck KGaA confirms deal on track Merck KGaA raised its 2026 outlook on August 6 and said it still expects to close the Bio-Techne purchase by late 2026 or early 2027, with about 140 million euros in annual cost savings. A healthy buyer with a firm timeline makes the $73 payout more certain.

    It shows the acquirer is financially strong and committed, which supports the deal price.

  • Weak quarterly sales and legal probe Bio-Techne's revenue fell 1.5% to $311.4 million, missing estimates, and a law firm is investigating whether the board handled the buyout fairly. These are minor now because the $73 cash deal caps the stock, but they could matter if the deal breaks.

    It gives the fair counterweight: the company's own results are soft and the deal faces a legal review.

Q2 2026
▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

  • Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.

    This is the single new event that explains the stock's move and future path.

  • Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.

    It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.

  • Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.

    It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

June 2026
▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

  • Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.

    This is the single new event that explains the stock's move and future path.

  • Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.

    It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.

  • Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.

    It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

▲1▼1

Merck KGaA to buy Bio-Techne for $73/share in $11.3B cash deal

  • Merck KGaA acquisition at $73/share cash Germany's Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, a 36% premium to its recent average price. This puts a firm floor under the stock near the deal price and is the main reason shares jumped about 20%.

    This is the single new event that explains the stock's move and future path.

  • Deal completion risk and timeline The deal needs regulatory approvals and a shareholder vote, and is expected to close in late 2026 or early 2027. Until then, the stock may trade below $73 if investors worry the deal could fall through, but the agreed price limits big downside.

    It is the main counterweight: the deal is not yet final, so the premium is not guaranteed.

  • Weak underlying quarterly revenue Bio-Techne's latest quarterly revenue fell 1.5% to $311.4 million and missed expectations. This weak operating performance is now less important because the company is being bought, but it shows why the standalone business was struggling.

    It explains the weak standalone backdrop that the buyout overrides, giving a fair picture.

Illumina Inc (ILMN)

Q3 2026
▲2▼1

Illumina Surges on Earnings Beat, S&P 500 Entry, Biotech Boom

  • Earnings Beat and Raised Guidance Illumina beat earnings and raised guidance, with revenue up 4.8% to $1.09 billion. Clinical sequencing demand stayed strong, growing 20% outside China, and NovaSeq X placements topped 80 units.

    This point explains the fundamental business strength that drove the stock higher.

  • S&P 500 Inclusion and Biotech Boom The stock gained 46% amid a biotech boom, and Illumina joined the S&P 500, attracting index-fund demand. Eli Lilly joined its Billion Cell Atlas, and Merck/Moderna's cancer vaccine success boosted shares 15.6%.

    This point captures the market and partnership catalysts that amplified the stock's rise.

  • Roche Launches Cheaper Competing Sequencer Roche launched a competing sequencer at $750,000, well below Illumina's $985,000–$1.25 million, threatening its ~70% market share and potentially forcing price cuts or slower sales. Analysts expect gradual share erosion rather than collapse.

    This point highlights the main competitive threat that could pressure future growth.

August 2026
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

Latest
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

July 2026
▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

© 2026 MarketDXWhy